Skip to main content
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc — Investor Relations & Filings

Ticker · SNDX ISIN · US87164F1057 LEI · 529900OF94TRHKZVBS87 US Manufacturing
Open in API
Filings indexed 620 across all filing types
Latest filing 2023-12-20 Capital/Financing Update
Country US United States of America
Listing US SNDX

About Syndax Pharmaceuticals Inc

https://syndax.com/

Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes therapies for various cancers. The company focuses on developing first-in-class and best-in-class treatments for areas with significant unmet medical needs, such as acute leukemias and chronic Graft-versus-Host Disease (GVHD). Its pipeline targets a range of hematological malignancies and solid tumors, utilizing approaches in epigenetics and immunomodulation to create transformative therapies.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 19, 2023, by Syndax Pharmaceuticals, Inc. The key content is an announcement of the closing of a recent public offering of common stock and the exercise of the underwriters' option to purchase additional shares. It includes a press release as an exhibit. The document does not contain detailed financial statements or comprehensive financial analysis but rather reports a financing event. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length is 3131 characters, which is relatively short but contains substantive information about the financing event, not just a report publication announcement or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2023-12-20 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 14, 2023, reporting the entry into a material definitive agreement related to an underwriting agreement for a stock offering. It details the terms of the offering, the parties involved, and includes exhibits such as the underwriting agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is an announcement of a financing event (stock offering) and related agreements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief notice or certification.
2023-12-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. This type of document is a capital markets filing that provides updates on financing activities and share issuance. It is not an annual report, earnings release, or management discussion, but specifically a financing update related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2023-12-15 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of $150 million shares of common stock by Syndax Pharmaceuticals, Inc. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and company overview. The document references SEC registration statements and is filed pursuant to Rule 424(b)(5), which is a form used for prospectus supplements related to securities offerings. The content focuses on the terms of the stock offering, underwriting details, and company business overview, which aligns with capital raising activities. There is no financial statement data or earnings information, nor is it an announcement of voting results or management changes. This document is clearly an update on financing activities and capital structure changes through a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2023-12-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes multiple press releases and references to an investor event, but it does not contain detailed financial statements or comprehensive financial analysis. The document length is 4112 characters, which is relatively short and mainly includes announcements of events and press releases. It does not present a full annual or quarterly report, nor detailed management discussion or earnings release. The content fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories.
2023-12-12 English
Regulatory Filings 2023
Regulatory Filings Classification · 80% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as any specific filing type. According to the fallback rule, documents that do not fit any specific category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable.
2023-12-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.